As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...

Lauren Martz, Senior Writer Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...

One component of Elias Zerhouni's multi-pronged strategy to access external innovation is the Sanofi-Sunrise initiative - a company-creation vehicle to accelerate translation of early stage technologies of strategic interest to the pharma. Launched in 2013, Sanofi-Sunrise...

Stephen Hansen, Associate Editor New revelations about the breadth of Warp Drive Bio LLC's platform, coupled with the lengthy biotech boom, led the company and partner Sanofi to toss out their 2012 build-to-buy deal in...